134 related articles for article (PubMed ID: 24443139)
21. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus.
Stevens J; Blixt O; Tumpey TM; Taubenberger JK; Paulson JC; Wilson IA
Science; 2006 Apr; 312(5772):404-10. PubMed ID: 16543414
[TBL] [Abstract][Full Text] [Related]
22. Structural Stability and Antigenicity of Universal Equine H3N8 Hemagglutinin Trimer upon Release from Polyanhydride Nanoparticles and Pentablock Copolymer Hydrogels.
Siddoway AC; Verhoeven D; Ross KA; Wannemuehler MJ; Mallapragada SK; Narasimhan B
ACS Biomater Sci Eng; 2022 Jun; 8(6):2500-2507. PubMed ID: 35604784
[TBL] [Abstract][Full Text] [Related]
23. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
24. Free energy simulations reveal a double mutant avian H5N1 virus hemagglutinin with altered receptor binding specificity.
Das P; Li J; Royyuru AK; Zhou R
J Comput Chem; 2009 Aug; 30(11):1654-63. PubMed ID: 19399777
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
26. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China.
Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS
Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547
[TBL] [Abstract][Full Text] [Related]
27. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
[TBL] [Abstract][Full Text] [Related]
28. Stable polyanhydride synthesized from sebacic acid and ricinoleic acid.
Haim-Zada M; Basu A; Hagigit T; Schlinger R; Grishko M; Kraminsky A; Hanuka E; Domb AJ
J Control Release; 2017 Jul; 257():156-162. PubMed ID: 27126904
[TBL] [Abstract][Full Text] [Related]
29. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
[TBL] [Abstract][Full Text] [Related]
30. Live vaccination with an H5-hemagglutinin-expressing infectious laryngotracheitis virus recombinant protects chickens against different highly pathogenic avian influenza viruses of the H5 subtype.
Pavlova SP; Veits J; Mettenleiter TC; Fuchs W
Vaccine; 2009 Aug; 27(37):5085-90. PubMed ID: 19573638
[TBL] [Abstract][Full Text] [Related]
31. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
[TBL] [Abstract][Full Text] [Related]
32. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
[TBL] [Abstract][Full Text] [Related]
33. Identifying discriminative amino acids within the hemagglutinin of human influenza A H5N1 virus using a decision tree.
Wu LC; Horng JT; Huang HD; Chen WL
IEEE Trans Inf Technol Biomed; 2008 Nov; 12(6):689-95. PubMed ID: 19000947
[TBL] [Abstract][Full Text] [Related]
34. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
35. Direct visualization of avian influenza H5N1 hemagglutinin precursor and its conformational change by high-speed atomic force microscopy.
Lim KS; Mohamed MS; Wang H; Hartono ; Hazawa M; Kobayashi A; Voon DC; Kodera N; Ando T; Wong RW
Biochim Biophys Acta Gen Subj; 2020 Feb; 1864(2):129313. PubMed ID: 30825615
[TBL] [Abstract][Full Text] [Related]
36. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).
Yang SG; Wo JE; Li MW; Mi FF; Yu CB; Lv GL; Cao HC; Lu HF; Wang BH; Zhu H; Li LJ
Vaccine; 2009 Dec; 27(52):7451-8. PubMed ID: 19450640
[TBL] [Abstract][Full Text] [Related]
37. Epitope mapping of neutralizing monoclonal antibody in avian influenza A H5N1 virus hemagglutinin.
Ohkura T; Kikuchi Y; Kono N; Itamura S; Komase K; Momose F; Morikawa Y
Biochem Biophys Res Commun; 2012 Feb; 418(1):38-43. PubMed ID: 22226969
[TBL] [Abstract][Full Text] [Related]
38. Crosslinked polyanhydrides for use in orthopedic applications: degradation behavior and mechanics.
Muggli DS; Burkoth AK; Anseth KS
J Biomed Mater Res; 1999 Aug; 46(2):271-8. PubMed ID: 10380006
[TBL] [Abstract][Full Text] [Related]
39. Protein stability in the presence of polymer degradation products: consequences for controlled release formulations.
Determan AS; Wilson JH; Kipper MJ; Wannemuehler MJ; Narasimhan B
Biomaterials; 2006 Jun; 27(17):3312-20. PubMed ID: 16504288
[TBL] [Abstract][Full Text] [Related]
40. Controlled delivery systems for proteins using polyanhydride microspheres.
Tabata Y; Gutta S; Langer R
Pharm Res; 1993 Apr; 10(4):487-96. PubMed ID: 8483830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
